Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMITRIPTYLINE

All products: general benefit

Other products in the same Health Canada class (N06AA) — coverage varies; not interchangeable

  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, Not a benefit
  • Doxepin (Sinequan): general benefit, Not a benefit
  • Imipramine (Tofranil): general benefit, Not a benefit
  • Nortriptyline (Aventyl): general benefit
  • Trimipramine (Surmontil): general benefit, Not a benefit

17 more in the class list below

Elavil · DIN 00335088 · 50mg · tablet

General benefitDormant since 2026-04-24 · checked 2026-09-20 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Elavil · DIN 00335088 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2026-04-24 · brand ELAVIL · ATC N06AA09 AMITRIPTYLINE · form Tablet · route Oral · ingredients AMITRIPTYLINE HYDROCHLORIDE 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1078 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2215 · Verify on the e-Formulary ↗ (DIN 00335088)

Source record
DIN 00335088: Elavil Raw flags: sec3=Y Item: 281604001; group id 452; item number 1127; lccId None; manufacturer id AAP Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2347; ministry $0.1078 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00335088 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2215
Interchangeable products
Jamp-Amitriptyline · DIN 02457687 · $0.1078 Mar-Amitriptyline · DIN 02429896 · $0.1078 PMS-Amitriptyline · DIN 00654507 · $0.1078
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since 2026-04-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: depressive illness
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: SERTRALINE HCL CITALOPRAM HYDROBROMIDE · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) Indications CELEXA (citalopram hydrobromide) is indicated for: • the symptomatic relief of depressive illness in adults The relapse rate was significantly lower in CELEXA-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with CELEXA (see 14.1 Clinical Trials by Indication). PM: https://pdf.hres.ca/dpd_pm/00082636.PDF; date not captured; DIN 02239607; fetched 2026-09-10 Product monograph MIRTAZAPINE · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) 1 INDICATIONS REMERON® (mirtazapine) is indicated for: • the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00075141.PDF; date May 4, 2021; DIN 02243910; fetched 2026-09-10 Product monograph SERTRALINE HCL · General benefit 1 INDICATIONS ZOLOFT (sertraline hydrochloride capsules) is indicated for: Adults  Depression ZOLOFT is indicated for the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00072140.PDF; date AUG 22, 2023; DIN 01962779; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS pms-AMITRIPTYLINE (amitriptyline hydrochloride) is indicated for: • Drug management of depressive illness. • Depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression. Endogenous depression is more likely to be alleviated than are other depressive states. pms-AMITRIPTYLINE, because of its sedative action, is also of value in alleviating the anxiety component of depression. As with other tricyclic antidepressants, pms-AMITRIPTYLINE may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions. 1.1 Pediatrics Pediatrics (˂ 18 years of age): Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00074345.PDF PM date: December 11, 1998 Source product: PMS-AMITRIPTYLINE; DIN 00654507; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)